| Literature DB >> 33841925 |
Feng Wang1, Shu-Geng Gao1, Qi Xue1, Feng-Wei Tan1, Yu-Shun Gao1, Da-Li Wang1, You-Sheng Mao1, Jun Zhao1, Yin Li1, Xiang-Yang Yu1, Hong Cheng1, Chen-Guang Zhao1, Ding Yang1, Ju-Wei Mu1.
Abstract
BACKGROUND: The purpose of this study was to explore the prognostic factors of oesophageal signet ring cell (SRC) carcinoma and to construct a nomogram for predicting the outcome of SRC carcinoma of oesophagus.Entities:
Keywords: Oesophageal cancer; nomogram; signet ring cell (SRC)
Year: 2021 PMID: 33841925 PMCID: PMC8024836 DOI: 10.21037/jtd-20-3084
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Figure 1Study diagram of the selection process. ICD-O-3, 3rd edition of the International Classification Disease for Oncology; WHO, World Health Organization.
Characteristics of oesophageal SRC carcinoma patients in the training cohort and validation cohort
| Variable | Total, N (%) | Training cohort, N (%) | Validation cohort, N (%) | P value |
|---|---|---|---|---|
| Total | 968 (100) | 677 (70.0) | 291 (30.0) | |
| Age | 0.912 | |||
| ≤75 | 744 (76.9) | 521 (77.0) | 223 (76.6) | |
| >75 | 224 (23.1) | 156 (23.0) | 68 (23.4) | |
| Sex | 0.317 | |||
| Female | 127 (13.1) | 84 (12.4) | 43 (14.8) | |
| Male | 841 (86.9) | 593 (87.6) | 248 (85.2) | |
| Marital status | 0.769 | |||
| Married | 612 (63.2) | 426 (62.9) | 186 (63.9) | |
| Single or unknown | 356 (36.8) | 251 (37.1) | 105 (36.1) | |
| Race | 0.137 | |||
| White | 914 (94.4) | 633 (93.5) | 281 (96.6) | |
| Black | 27 (2.8) | 23 (3.4) | 4 (1.4) | |
| Others | 27 (2.8) | 21 (3.1) | 6 (2.1) | |
| Site | 0.860 | |||
| Cervical | 1 (0.1) | 1 (0.1) | 0 (0) | |
| Thoracic | 12 (1.2) | 8 (1.2) | 4 (1.4) | |
| Abdominal | 5 (0.5) | 4 (0.6) | 1 (0.3) | |
| Upper third | 5 (0.5) | 4 (0.6) | 1 (0.3) | |
| Middle third | 47 (4.9) | 29 (4.3) | 18 (6.2) | |
| Lower third | 825 (85.2) | 577 (85.2) | 248 (85.2) | |
| Overlapping | 38 (3.9) | 29 (4.3) | 9 (3.1) | |
| Oesophagus, NOS | 35 (3.6) | 25 (3.7) | 10 (3.4) | |
| Grade | 0.547 | |||
| I | 3 (0.3) | 3 (0.4) | 0 (0) | |
| II | 35 (3.6) | 25 (3.7) | 10 (3.4) | |
| III | 755 (78.0) | 531 (78.4) | 224 (77.0) | |
| IV | 22 (2.3) | 17 (2.5) | 5 (1.7) | |
| Unknown | 153 (15.8) | 101 (14.9) | 52 (17.9) | |
| Invasion of the surrounding tissue | 0.238 | |||
| Yes | 150 (15.5) | 111 (16.4) | 39 (13.4) | |
| No | 818 (84.5) | 566 (83.6) | 252 (86.6) | |
| Lymph node metastasis | 0.390 | |||
| Yes | 562 (58.1) | 387 (57.2) | 175 (60.1) | |
| No | 406 (41.9) | 290 (42.8) | 116 (39.9) | |
| Distant metastasis | 0.322 | |||
| Yes | 291 (30.1) | 210 (31.0) | 81 (27.8) | |
| No | 677 (69.9) | 467 (69.0) | 210 (72.2) | |
| Surgery | 0.223 | |||
| No surgery | 607 (62.7) | 429 (63.4) | 178 (61.2) | |
| Local destruction or excision | 24 (2.5) | 13 (1.9) | 11 (3.8) | |
| Surgery | 337 (34.8) | 235 (34.7) | 102 (35.1) | |
| Radiation therapy | 0.634 | |||
| Yes | 266 (27.5) | 183 (27.0) | 83 (28.5) | |
| No | 702 (72.5) | 494 (73.0) | 208 (71.5) | |
| Chemotherapy | 0.580 | |||
| Yes | 690 (71.3) | 479 (70.8) | 211 (72.5) | |
| No or unknown | 278 (28.7) | 198 (29.2) | 80 (27.5) | |
| Number of malignant tumours | 0.243 | |||
| =1 | 752 (77.7) | 519 (76.7) | 233 (80.1) | |
| ≥2 | 216 (22.3) | 158 (23.3) | 58 (19.9) |
Figure 2Kaplan‐Meier survival curves of the overall survival (OS) for oesophageal signet ring carcinoma patients. (A) Training cohort; (B) validation cohort.
Univariate cox analysis of overall survival in the training cohort
| Variable | HR | 95% CI | P value |
|---|---|---|---|
| Age | 0.040 | ||
| ≤75 | Reference | ||
| >75 | 1.222 | 1.009–1.480 | 0.040 |
| Sex | 0.675 | ||
| Female | Reference | ||
| Male | 0.948 | 0.738–1.217 | 0.675 |
| Marital status | <0.001 | ||
| Single or unknown | Reference | ||
| Married | 0.733 | 0.620–0.868 | <0.001 |
| Race | 0.445 | ||
| White | Reference | ||
| Black | 1.299 | 0.855–1.972 | 0.220 |
| Others | 1.094 | 0.692–1.729 | 0.701 |
| Site | 0.672 | ||
| Cervical | Reference | ||
| Thoracic | 0.327 | 0.039–2.723 | 0.301 |
| Abdominal | 0.356 | 0.037–3.429 | 0.371 |
| Upper third | 0.171 | 0.015–1.897 | 0.150 |
| Middle third | 0.499 | 0.067–3.695 | 0.496 |
| Lower third | 0.482 | 0.068–3.437 | 0.467 |
| Overlapping | 0.589 | 0.080–4.348 | 0.604 |
| Oesophagus, NOS | 0.485 | 0.065–3.620 | 0.480 |
| Grade | 0.886 | ||
| I | Reference | ||
| II | 1.576 | 0.369–6.723 | 0.539 |
| III | 1.725 | 0.430–6.920 | 0.442 |
| IV | 1.48 | 0.336–6.513 | 0.604 |
| Unknown | 1.777 | 0.437–7.225 | 0.422 |
| Invasion of the surrounding tissue | <0.001 | ||
| No | Reference | ||
| Yes | 1.898 | 1.534–2.347 | <0.001 |
| Lymph node metastasis | <0.001 | ||
| No | Reference | ||
| Yes | 1.341 | 1.134–1.586 | <0.001 |
| Distant metastasis | <0.001 | ||
| No | Reference | ||
| Yes | 2.509 | 2.100–2.998 | <0.001 |
| Surgery | <0.001 | ||
| No surgery | Reference | ||
| Local destruction or excision | 0.501 | 0.274–0.913 | 0.024 |
| Surgery | 0.364 | 0.302–0.439 | <0.001 |
| Radiation therapy | <0.001 | ||
| No | Reference | ||
| Yes | 0.507 | 0.418–0.616 | <0.001 |
| Chemotherapy | <0.001 | ||
| No or unknown | Reference | ||
| Yes | 0.628 | 0.525–0.751 | <0.001 |
| Number of malignant tumours | 0.116 | ||
| =1 | Reference | ||
| ≥2 | 0.856 | 0.706–1.039 | 0.116 |
HR, hazard ratio; CI, confidence interval.
Multivariate cox analysis of overall survival in the training cohort
| Variable | HR | 95% CI | P value |
|---|---|---|---|
| Age | 0.901 | ||
| ≤75 | Reference | ||
| >75 | 0.987 | 0.805–1.211 | 0.901 |
| Marital status | 0.090 | ||
| Single or unknown | Reference | ||
| Married | 0.862 | 0.726–1.024 | 0.090 |
| Invasion of the surrounding tissue | <0.001 | ||
| No | Reference | ||
| Yes | 1.431 | 1.147–1.784 | <0.001 |
| Lymph node metastasis | <0.001 | ||
| No | Reference | ||
| Yes | 1.446 | 1.214–1.723 | <0.001 |
| Distant metastasis | <0.001 | ||
| No | Reference | ||
| Yes | 1.882 | 1.553–2.281 | <0.001 |
| Surgery | <0.001 | ||
| No surgery | Reference | ||
| Local destruction or excision | 0.516 | 0.279–0.953 | 0.034 |
| Surgery | 0.419 | 0.342–0.514 | <0.001 |
| Chemotherapy | <0.001 | ||
| No or unknown | Reference | ||
| Yes | 0.487 | 0.402–0.591 | <0.001 |
HR, hazard ratio; CI, confidence interval.
Figure 3Nomogram for predicting 1-, 3- and 5-year overall survival of patients with oesophageal signet ring cell carcinoma.
Figure 4Calibration curves for predicting 3-year overall survival in the training cohort (A) and validation cohort (B).
Figure 5Decision curve analysis of the nomogram for predicting overall survival at 1-year point in the trainning cohort (A) and validation cohort (B) and overall survival at 3-year point in the trainning cohort (C) and validation cohort (D).